Global pharmaceutical companies are increasingly moving toward equity-based collaborations, instead of traditional licensing arrangements, and China has become a key stage for this transformation. The "NewCo" model, where partners jointly establish a new entity to drive innovation (and often accompanied by financial investors and incubators), offers a strategic alternative for cross-border partnerships. In many cases, Chinese companies use this structure to license out their innovative assets, but we also see foreign companies adopting it to introduce their products into China.

Unlike conventional licensing, which provides licensors with immediate financial returns, the NewCo approach ties value realization to long-term development. Typically, the licensor grants exclusive regional rights to the NewCo (mostly limited to non-PRC regional rights where there is a PRC licensor) while also holding equity, creating a dual role as shareholder and technology provider. This structure allows licensors greater influence over pipeline progress and strategic decisions. Although early cash flow is slower, successful execution can deliver substantial upside through future licensing-out, mergers and acquisitions, or public listings. Beyond milestone payments, licensors benefit from equity appreciation and dividends, making this model appealing for those aiming to capture downstream value.

However, the complexity of NewCo arrangements demands careful legal and regulatory planning. Intellectual property arrangements must be clearly defined, including retained rights, improvements, and non-compete obligations. Technology and data transfers introduce additional challenges, as Chinese regulations governing technology import/export, data, and human genetic resources impose strict approval and filing requirements. Geopolitical dynamics further complicate cross-border flows, making location strategy critical. Against this backdrop, companies should prioritize early alignment on governance, compliance, and risk mitigation to ensure the structure remains resilient amid regulatory and market uncertainties.

Exit strategies under the NewCo model are rarely simple. Terminating a license does not automatically resolve equity entanglements, and shareholder agreements often include drag-along, tag-along, and rights of first refusal/offer that restrict flexibility. Common exit routes under the NewCo model, like IPO, SPAC, asset sale, or liquidation, depend on factors far beyond a single product's success, such as pipeline breadth, market conditions, and financing rounds. This unpredictability contrasts sharply with the relative certainty of milestone-based payments under traditional licensing, and losses remain a real possibility.

The NewCo model offers strategic control and long-term potential, but success requires foresight. Companies must align intellectual property frameworks, compliance protocols, and exit flexibility from the outset. In China's evolving regulatory and geopolitical landscape, robust governance and a clear roadmap for collaboration and disengagement are essential to turn opportunity into sustainable value.